ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2083

Comparing the Electronic Patient Reported Outcome (ePro) Tool Versus the Paper Reported Outcome (pPro) Tool in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

Charles Inderjeeth1, Warren Raymond2 and Andrisha Inderjeeth3, 1Rheumatology And Rehab and Aged Care, University of western Australia, North Metro Health Service, Perth WA, Australia, 2Rheumatology and Geriatric Medicine, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Australia, 3Sir Charles Gairdner Hospital, Perth, Australia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: assessment and patient engagement, Electronic Health Record

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: ARHP IV: Clinical Practice, Patient Care and Health Services

Session Type: ARHP Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Clinical disease activity for patients with rheumatoid arthritis requires frequent monitoring for optimal management. Patient reported outcome (PRO) tools provide information that complements physician’s assessment of changes in disease activity and response to treatment. The use of electronic data capturing (ePRO) is potentially advantageous over paper based (pPRO) in terms of reducing missing data, reducing ambiguous responses and allowing time-stamped records and analysis.

Methods: Patients were assigned randomly to either ePRO or pPRO at visit one. At visit 2, patients crossed over into the other PRO modality (both pre-treatment) and remained in that arm for subsequent visits at week 6, 12 and 36. Patient assessments included 28 swollen (SJC) and tender joint counts (TJC), Patient assessment of pain (PAAP), Patient assessment of global disease activity (PtGADA) and Bristol Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ). 

Results: 52 patients with mean RA duration 11.7 years were enrolled and. Mean age was 55.7 (SD 14.3) years and 67% were female.

There was moderate to high correlation (Table 1) and agreement (Figure 1) between Nurse-Patient-Physician PRO assessments. There was no significant difference in PtGADA, PAAP and BRAF-MDQ between ePRO and pPRO assessments.

Patients reported high levels of satisfaction with both PRO arms with only 2 patients (8.3%) reporting dissatisfaction. 88-92% reported that they were either satisfied or very satisfied with either tool. 58% of those who transitioned from ePRO to pPRO had no preference for one over the other format whereas 67% of those who transitioned from pPRO to ePRO preferred the electronic tablet.

Conclusion: Both ePRO and pPRO provided consistent results and demonstrated equivalence in PRO assessment. ePRO was well embraced by patients with only a minority reporting dissatisfaction. It may be a desirable inclusion in routine RA and potentially other disease assessments for its added reliability, consistency and increased patient involvement.

Acknowledgements

1.    UCB Australia for  financial support

2.    Australian Rheumatologists for supplying patient data.  


Disclosure: C. Inderjeeth, None; W. Raymond, None; A. Inderjeeth, None.

To cite this abstract in AMA style:

Inderjeeth C, Raymond W, Inderjeeth A. Comparing the Electronic Patient Reported Outcome (ePro) Tool Versus the Paper Reported Outcome (pPro) Tool in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparing-the-electronic-patient-reported-outcome-epro-tool-versus-the-paper-reported-outcome-ppro-tool-in-rheumatoid-arthritis-patients-treated-with-certolizumab-pegol/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-the-electronic-patient-reported-outcome-epro-tool-versus-the-paper-reported-outcome-ppro-tool-in-rheumatoid-arthritis-patients-treated-with-certolizumab-pegol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology